Berkeley Capital Partners LLC Raises Position in Novartis AG (NYSE:NVS)
Berkeley Capital Partners LLC Raises Position in Novartis AG (NYSE:NVS)
Novartis (NYSE:NVS – Get Rating) last released its quarterly earnings data on Monday, July 18th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.04. The business had revenue of $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 EPS. As a group, equities analysts anticipate that Novartis AG will post 6.06 earnings per share for the current fiscal year. Berkeley Capital Partners LLC boosted its stake in Novartis AG (NYSE:NVS – Get Rating) by 226.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,557 shares of the company's stock after buying an additional 8,713 shares during the quarter. Berkeley Capital Partners LLC's holdings in Novartis were worth $1,102,000 at the end of the most recent reporting period.
伯克利資本合夥公司最近向美國證券交易委員會提交的13F文件顯示，今年第一季度，該公司將其在諾華製藥(紐約證券交易所代碼：NVS-GET Rating)的持股比例提高了226.7%。該機構投資者在本季度額外購買了8,713股後，持有該公司12,557股股票。在最近一個報告期結束時，Berkeley Capital Partners LLC持有的諾華公司股份價值1,102,000美元。
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. AHL Investment Management Inc. purchased a new position in Novartis in the 4th quarter worth approximately $25,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in Novartis in the 4th quarter worth approximately $32,000. Atwood & Palmer Inc. lifted its stake in Novartis by 400.0% in the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock worth $33,000 after purchasing an additional 300 shares in the last quarter. DeDora Capital Inc. purchased a new position in Novartis in the 1st quarter worth approximately $34,000. Finally, Allegheny Financial Group LTD acquired a new stake in shares of Novartis during the 4th quarter worth approximately $34,000. 9.40% of the stock is owned by hedge funds and other institutional investors.
一些其他對衝基金和其他機構投資者最近也買賣了該股的股票。AHL投資管理公司在第四季度購買了諾華公司價值約25,000美元的新頭寸。Dixon Hughes Goodman Wealth Advisors LLC在第四季度購買了諾華公司的一個新頭寸，價值約3.2萬美元。今年第一季度，阿特伍德-帕爾默公司增持諾華股份400.0%。Atwood&Palmer Inc.現在持有375股該公司股票，價值3.3萬美元，該公司在上個季度又購買了300股。DeDora Capital Inc.在第一季度購買了諾華公司的一個新頭寸，價值約3.4萬美元。最後，阿勒格尼金融集團有限公司在第四季度收購了價值約3.4萬美元的諾華公司新股。該公司9.40%的股票由對衝基金和其他機構投資者持有。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of analysts have recently issued reports on NVS shares. Wolfe Research downgraded shares of Novartis from an "outperform" rating to a "market perform" rating in a report on Monday, May 9th. Credit Suisse Group raised their price target on shares of Novartis from CHF 85 to CHF 88 in a report on Thursday, April 28th. JPMorgan Chase & Co. raised their price target on shares of Novartis from CHF 80 to CHF 81 and gave the stock an "underweight" rating in a report on Wednesday, July 20th. upgraded shares of Novartis from a "hold" rating to a "buy" rating in a report on Thursday, April 14th. Finally, UBS Group lifted their target price on shares of Novartis from CHF 85 to CHF 88 and gave the company a "neutral" rating in a report on Wednesday, April 27th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $87.33.
一些分析師最近發佈了關於NVS股票的報告。沃爾夫研究公司在5月9日星期一的一份報告中將諾華公司的股票評級從“跑贏大盤”下調至“市場表現”。瑞士信貸集團在4月28日星期四的一份報告中將諾華公司的股票目標價從85瑞士法郎上調至88瑞士法郎。摩根大通在7月20日星期三的一份報告中將諾華公司的股票目標價從80瑞士法郎上調至81瑞士法郎，並將該股的評級定為“減持”。在4月14日週四的一份報告中，諾華公司的股票評級從持有上調至買入。最後，瑞銀集團在4月27日星期三的一份報告中將諾華公司的股票目標價從85瑞士法郎上調至88瑞士法郎，並給予該公司“中性”評級。兩名研究分析師對該股的評級為賣出，8名分析師給予持有評級，3名分析師給予買入評級，一名分析師給予該公司強烈買入評級。根據MarketBeat.com的數據，該股的共識評級為持有，共識目標價為87.33美元。
Novartis Stock Performance
諾華公司股票表現
Novartis (NYSE:NVS – Get Rating) last released its quarterly earnings data on Monday, July 18th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.04. The business had revenue of $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 EPS. As a group, equities analysts anticipate that Novartis AG will post 6.06 earnings per share for the current fiscal year.
諾華公司(紐約證券交易所代碼：NVS-GET Rating)最近一次發佈季度收益數據是在7月18日星期一。該公司公佈本季度每股收益(EPS)為1.56美元，比普遍預期的1.52美元高出0.04美元。該業務當季營收為127.8億美元，高於分析師預期的127.8億美元。諾華的淨利潤率為44.31%，股本回報率為21.88%。該公司本季度營收同比下降1.4%。去年同期，該公司每股收益為1.64美元。作為一個整體，股票分析師預計諾華製藥本財年的每股收益將達到6.06歐元。
Novartis Company Profile
諾華公司簡介
(Get Rating)
(獲取評級)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
諾華製藥在全球研究、開發、製造和營銷保健品。該公司通過兩個部門運營，創新藥品和Sandoz。創新藥品部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝科、皮膚科、呼吸科、心血管、腎臟和新陳代謝藥物產品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter's Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- MarketBeat：回顧一週7/25-7/29
- 寶潔第四季度收益開始疲軟
- 在投資INTC股票之前，你必須問一個問題
- 家得寶：引領熊市的美麗而乏味的股票
- CRISPR治療公司可能是隱藏在平坦視線中的登月計劃嗎？
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。